National Institute on Aging

Thought Leaders, Entrepreneurs and Active Investors Come Together to Shape Innovation at the 21st Annual What's Next Longevity Venture Summit

Retrieved on:

Tuesday, April 9, 2024

Dark, Fairmont San Francisco, Head, Conference, MFA, Longevity, AARP, Government, Learning, Growth, Incubator, Running, AI, Investment banking, Ziegler, Housing, Summit, NIA, National Institute on Aging

LAFAYETTE, Calif., April 9, 2024 /PRNewswire/ -- Mary Furlong & Associates (MFA), producer of the longest running conference on the longevity economy, announced that the What's Next Longevity Venture Summit, will bring together thought leaders, including active investors, entrepreneurs, incubators, nonprofits, government agencies, providers and companies focused on the $9.5 trillion longevity market, June 11-12 at the Fairmont San Francisco. The theme, Net New: Investment, AI & Innovation In the Longevity Marketplace, will drive discussions on the key challenges and opportunities for those supporting the age 50+ market.

Key Points:

The theme, Net New: Investment, AI & Innovation In the Longevity Marketplace, will drive discussions on the key challenges and opportunities for those supporting the age 50+ market.
"We put a laser focus on the active investors in the space today, highlighting the investment opportunities as well as forming partnerships for success in longevity.
And, to demonstrate their continued commitment to the Summit, the AgeTech Collaborative from AARP will be the title sponsor of this year's conference."
The What's Next Longevity Venture Summit will take place at the Fairmont San Francisco, June 11-12.

Congress Passes Bills Making Major Investments in Alzheimer’s

Retrieved on:

Saturday, March 23, 2024

Congress, Medical imaging, Caregiver, Health equity, DSM-IV codes, Research, National Institute on Aging, National coverage determination, Investment, CDC, NINDS, Language, Dementia, NIA, Medicare, NCD, CMS, Pharmaceutical industry

WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.

Key Points:

WASHINGTON, March 23, 2024 (GLOBE NEWSWIRE) -- As part of a budget bill heading to President Biden for his signature, Congress passed major investments in the fight against Alzheimer’s; specifically demonstrating its unwavering commitment to equity and inclusion in the reporting language, which helps to foster a more equitable and just healthcare system.
“We are thrilled to witness Congress’s steadfast 12-year commitment to Alzheimer’s research, despite ongoing budget restraints,” said UsAgainstAlzheimer’s chair and co-founder George Vradenburg.
UsAgainstAlzheimer’s worked to include language encouraging diversity in clinical trials, and the establishment of a brain health equity initiative to improve the integration of brain health into primary care, particularly within underrepresented communities.
The bill also encourages the National Institute of Biomedical Imaging and Bioengineering to collaborate with National Institute of Aging (NIA) and The National Institute of Neurological Disorders and Stroke (NINDS) to develop new technologies that could discover the earliest biological events that lead to Alzheimer’s disease and related dementias.

Parkinson's Foundation to Accelerate Research Through Expanded Genetic Testing and Counseling Study

Retrieved on:

Tuesday, February 6, 2024

NEW YORK and MIAMI, Feb. 6, 2024 /PRNewswire/ -- Through its Global Parkinson's Genetics Program (GP2), Aligning Science Across Parkinson's (ASAP) has awarded the Parkinson's Foundation a grant that will significantly expand its landmark international genetics study, PD GENEration: Mapping the Future of Parkinson's Disease. The study provides genetic testing and genetic counseling to people with Parkinson's disease (PD). ASAP's funding will allow the Foundation to accelerate the study's impact by focusing on those who have been historically underrepresented in research.

Key Points:

The study provides genetic testing and genetic counseling to people with Parkinson's disease (PD).
ASAP's funding will allow the Foundation to accelerate the study's impact by focusing on those who have been historically underrepresented in research.
It is a patient-facing research study," said Parkinson's Foundation Senior Vice President and Chief Scientific Officer James Beck, PhD.
Fox Foundation for Parkinson's Research is ASAP's implementation partner and issued the grants on behalf of ASAP and GP2.

Amydis Receives $3.4 million NIH Commercialization Readiness Pilot Grant Award to Map Heterogeneity of Alzheimer’s Diseases in Human Clinical Trial Using Novel Retinal Tracer

Retrieved on:

Tuesday, November 14, 2023

Eye, CRP, Alpha-synuclein, ALS, SAN, National Institute on Aging, Database, Genomics, Patient, Research, Dementia, Trial of the century, Biomarker, Central nervous system, Physician, Bangladesh Technical Education Board, Health, Medical imaging

The grant will fund the use of novel fluorescent tracers to develop a comprehensive retinal biomarker database that maps the heterogeneity of Alzheimer’s pathogenesis.

Key Points:

The grant will fund the use of novel fluorescent tracers to develop a comprehensive retinal biomarker database that maps the heterogeneity of Alzheimer’s pathogenesis.
Amydis is developing a platform of proprietary small molecule tracers that bind to misfolded protein deposits, including amyloid beta, alpha-synuclein and TDP-43.
“Our tracer enables the creation of a first-in-class multi-modal retinal image database that includes biomarkers in central nervous system tissue that characterize Alzheimer’s disease.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

New Publication: Scientists from National Institute on Aging, Amazentis and EPFL Publish Landmark Paper on an Essential Biological Pathway for Healthy Aging

Retrieved on:

Thursday, December 7, 2023

LAUSANNE, Switzerland, Dec. 7, 2023 /PRNewswire/ -- Timeline Nutrition announces the publication of a landmark scientific paper in Nature Metabolism, "Mitophagy in human health, aging and disease," a collaboration from the head of the National Institute on Aging (NIA), Prof. Luigi Ferrucci, and the Amazentis research team, led by Dr. Davide D'Amico. The review is coauthored by Professor Johan Auwerx from the prestigious Swiss Federal Institute of Technology (EPFL), Dr. Julie Faitg and Professor Anna Picca.

Key Points:

The review is coauthored by Professor Johan Auwerx from the prestigious Swiss Federal Institute of Technology (EPFL), Dr. Julie Faitg and Professor Anna Picca.
With aging often comes a lack of energy, but what if it was the other way around?
Impaired mitophagy can lead to chronic, low-grade inflammation and weakened immune response in the elderly, a condition known as "inflammaging."
To learn more about Mitopure (Urolithin A) and how Timeline Nutrition is using these insights to develop innovative nutritional products, visit www.timelinenutrition.com .

10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain

Retrieved on:

Thursday, December 7, 2023

PLEASANTON, Calif., Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research.

Key Points:

PLEASANTON, Calif., Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research.
"Our goal is to provide researchers with a highly detailed genetic map of the damage caused in neurodegenerative disorders," said Andrew B. Singleton, Ph.D., NIH CARD director.
NIH CARD scientists aim to produce high-quality, standardized and harmonized datasets that can be integrated with other modalities, like long-read DNA sequencing.
NIH CARD is a collaborative initiative of the National Institute on Aging (NIA) and National Institute of Neurological Disorders and Stroke.

AX3 ® Bio-Pure Astaxanthin Extends Lifespan in NIH-Funded Longevity Study

Retrieved on:

Wednesday, December 6, 2023

HONOLULU, Dec. 6, 2023 /PRNewswire-PRWeb/ -- AX3 Life, a human longevity company, announced breakthrough life extension findings related to its longevity supplement, AX3® Bio-Pure Astaxanthin—a highly bioavailable, pure, and environmentally sustainable form of astaxanthin that safely fights inflammaging and other hallmarks of aging to improve lifespan and healthspan.

Key Points:

The ITP is widely recognized as the gold standard in longevity research and uses lifespan as its primary endpoint.
Conducting lifespan studies in humans would require decades, so the ITP's rigorous testing of lifespan in laboratory mice represents the most credible and practical assessment of mammalian lifespan presently available.
Results of the multi-year ITP study demonstrated that AX3® Bio-Pure Astaxanthin extended the median lifespan of male mice by 12% with strong statistical significance (p=0.003).
"This study underscores why astaxanthin, and in particular AX3® Bio-Pure Astaxanthin, should be a key part of everyone's longevity regimen."

XPRIZE LAUNCHES LARGEST COMPETITION IN HISTORY - $101M XPRIZE HEALTHSPAN TO DRIVE HEALTHIER AGING FOR ALL

Retrieved on:

Wednesday, November 29, 2023

RIYADH, Saudi Arabia, Nov. 29, 2023 /PRNewswire/ -- XPRIZE, the world's leader in designing and operating large-scale incentive competitions to solve humanity's grand challenges, today launches $101M XPRIZE Healthspan. This 7-year global competition is the largest competition in history and the largest XPRIZE to date, offering $111 million total between the prize purse and a bonus award. XPRIZE Healthspan will award $101 million in prize funding to the team who successfully develops a proactive, accessible therapeutic that restores muscle, cognition, and immune function by a minimum of 10 years, with a goal of 20 years, in persons aged 65-80 years, in one year or less. An additional $10M FSHD Bonus Prize will be awarded to a team that demonstrates the ability to restore lost muscular function due to Facioscapulohumeral Muscular Dystrophy (FSHD) in one year or less. The announcement was made today alongside Co-Title Sponsors Hevolution Foundation and SOLVE FSHD as part of Hevolution's Global Healthspan Summit, the largest convening of its kind bringing together researchers, innovators, and entrepreneurs in the field of healthspan science taking place in Riyadh, Saudi Arabia.

Key Points:

This 7-year global competition is the largest competition in history and the largest XPRIZE to date, offering $111 million total between the prize purse and a bonus award.
"As the single-largest XPRIZE Healthspan funder, Hevolution Foundation is committed to advancing geroscience and reshaping the approach to aging," said Dr. Mehmood Khan, CEO, Hevolution Foundation, Co-Title Sponsor of XPRIZE Healthspan.
This initiative serves as yet another illustration of our enduring commitment to transforming aging treatments and championing healthy aging for everyone."
By developing therapeutics that target biological aging rather than disease, we can revolutionize the way we think about and treat aging," said Jamie Justice, Ph.D., Executive Director of XPRIZE Healthspan, XPRIZE.

The Care Economy Takes Center Stage at Conference Convening Policymakers, Nonprofits, Entrepreneurs, Investors and Media Focused on Aging and Caregiving

Retrieved on:

Monday, November 20, 2023

WASHINGTON, Nov. 20, 2023 /PRNewswire/ -- The sixth annual What's Next Longevity Innovation Summit presented by Mary Furlong and Associates will gather thought leaders at the National Press Club here December 12-13 to discuss "Investment and Innovation in the Care Economy," a $648 billion market opportunity. With the ranks of America's 53 million family caregivers and professional care workers expected to grow with the increasing older population, this conference brings together diverse perspectives from government agencies, nonprofits, entrepreneurs, investors, media and others focused in the $9.5 trillion longevity economy representing 46% of gross domestic product, according to AARP, the lead sponsor for the event.

Key Points:

With the ranks of America's 53 million family caregivers and professional care workers expected to grow with the increasing older population, this conference brings together diverse perspectives from government agencies, nonprofits, entrepreneurs, investors, media and others focused in the $9.5 trillion longevity economy representing 46% of gross domestic product, according to AARP, the lead sponsor for the event.
"According to the World Economic Forum, the Care Economy is the fastest growth economy globally with more caregivers needed for aging baby boomers and the oldest millennials who are turning 50 by 2030 when we will have an estimated 74.1 million Americans over the age of 65.
Our learning and networking event includes an 'ideation' session where all attendees will tackle a key caregiving issue resulting in a white paper from the group."
Founded in 2003, Mary Furlong & Associates (MFA) is a concierge consulting firm in the $8.3 trillion longevity market, with expertise in investment and entrepreneurism.

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

Retrieved on:

Tuesday, November 7, 2023

PURCHASE, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), (the “Company” or “Cognition”), today announced that the last participant was randomized in the Phase 2 SHINE study (NCT03507790) of CT1812, the company’s lead candidate for the treatment of age-related neurodegenerative diseases of the CNS and retina. A total of 153 adults with mild-to-moderate (MMSE 18-26) Alzheimer's disease were randomized to receive either placebo or oral doses of CT1812 (100 mg or 300 mg). Endpoints include safety, change in cognitive function, as measured by ADAS-Cog 11 and biomarker evidence of disease modification. Top-line results are expected in mid 2024 after the last participants have completed six months of treatment.

Key Points:

A total of 153 adults with mild-to-moderate (MMSE 18-26) Alzheimer's disease were randomized to receive either placebo or oral doses of CT1812 (100 mg or 300 mg).
Endpoints include safety, change in cognitive function, as measured by ADAS-Cog 11 and biomarker evidence of disease modification.
“Results of the SHINE trial will provide important information on safety, tolerability and cognitive effects of CT1812 in people with mild-to-moderate Alzheimer’s disease, and these results will inform our plans for Phase 3 development,” Lisa Ricciardi , president and CEO of Cognition Therapeutics stated.
“Completing enrollment in the trial ahead of our 2023 target allows us to bring proof-of-concept results sooner and provides savings to our company.